Lexicon Study Finds Sotagliflozin Improves Outcomes in HFpEF Patients Without Diabetes

Reuters11-10

Lexicon Study Finds Sotagliflozin Improves Outcomes in HFpEF Patients Without Diabetes

Lexicon Pharmaceuticals Inc. has announced new clinical data from a study evaluating sotagliflozin in patients with heart failure with preserved ejection fraction (HFpEF) without diabetes. The results were presented at the American Heart Association (AHA) Annual Scientific Sessions 2025. The randomized, double-blind, placebo-controlled trial, conducted under the direction of Dr. Juan J Badimon at Mount Sinai Medical Center, enrolled 88 racially diverse participants, 70 percent of whom were female. Over a six-month treatment period, patients receiving sotagliflozin demonstrated statistically significant improvements in left ventricular mass, diastolic function, six-minute walk test performance, and Kansas City Cardiomyopathy Questionnaire (KCCQ) scores compared to placebo. While peak VO2 improvement was not statistically significant, a notable trend was observed. This study is reported as the first to demonstrate clinical benefits of sotagliflozin for HFpEF patients without diabetes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571873-en) on November 08, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582817000?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 10:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582817000","market":"us","top_or_hot":-1,"title":"Lexicon Study Finds Sotagliflozin Improves Outcomes in HFpEF Patients Without Diabetes","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lexicon Study Finds Sotagliflozin Improves Outcomes in HFpEF Patients Without Diabetes\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lexicon Pharmaceuticals Inc. has announced new clinical data from a study evaluating sotagliflozin in patients with heart failure with preserved ejection fraction (HFpEF) without diabetes. The results were presented at the American Heart Association (AHA) Annual Scientific Sessions 2025. The randomized, double-blind, placebo-controlled trial, conducted under the direction of Dr. Juan J Badimon at Mount Sinai Medical Center, enrolled 88 racially diverse participants, 70 percent of whom were female. Over a six-month treatment period, patients receiving sotagliflozin demonstrated statistically significant improvements in left ventricular mass, diastolic function, six-minute walk test performance, and Kansas City Cardiomyopathy Questionnaire (KCCQ) scores compared to placebo. While peak VO2 improvement was not statistically significant, a notable trend was observed. This study is reported as the first to demonstrate clinical benefits of sotagliflozin for HFpEF patients without diabetes.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571873-en) on November 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lexicon Study Finds Sotagliflozin Improves Outcomes in HFpEF Patients Without Diabetes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLexicon Study Finds Sotagliflozin Improves Outcomes in HFpEF Patients Without Diabetes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-10 10:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lexicon Study Finds Sotagliflozin Improves Outcomes in HFpEF Patients Without Diabetes\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lexicon Pharmaceuticals Inc. has announced new clinical data from a study evaluating sotagliflozin in patients with heart failure with preserved ejection fraction (HFpEF) without diabetes. The results were presented at the American Heart Association (AHA) Annual Scientific Sessions 2025. The randomized, double-blind, placebo-controlled trial, conducted under the direction of Dr. Juan J Badimon at Mount Sinai Medical Center, enrolled 88 racially diverse participants, 70 percent of whom were female. Over a six-month treatment period, patients receiving sotagliflozin demonstrated statistically significant improvements in left ventricular mass, diastolic function, six-minute walk test performance, and Kansas City Cardiomyopathy Questionnaire (KCCQ) scores compared to placebo. While peak VO2 improvement was not statistically significant, a notable trend was observed. This study is reported as the first to demonstrate clinical benefits of sotagliflozin for HFpEF patients without diabetes.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571873-en) on November 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210150020.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL9rNgNP:1","article_id":"2582817000","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582817000","pubTimestamp":1762740538,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lexicon Pharmaceuticals Inc. has announced new clinical data from a study evaluating sotagliflozin in patients with heart failure with preserved ejection fraction  without diabetes. The results were presented at the American Heart Association  Annual Scientific Sessions 2025. The randomized, double-blind, placebo-controlled trial, conducted under the direction of Dr. Juan J Badimon at Mount Sinai Medical Center, enrolled 88 racially diverse participants, 70 percent of whom were female. Over a six-month treatment period, patients receiving sotagliflozin demonstrated statistically significant improvements in left ventricular mass, diastolic function, six-minute walk test performance, and Kansas City Cardiomyopathy Questionnaire  scores compared to placebo. While peak VO2 improvement was not statistically significant, a notable trend was observed. This study is reported as the first to demonstrate clinical benefits of sotagliflozin for HFpEF patients without diabetes.Disclaimer: This news","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LXRX":"莱斯康制药","BK4139":"生物科技","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4112":"金融交易所和数据","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4007":"制药","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"Lexicon研究发现Sotagliflozin可改善无糖尿病HFpEF患者的预后","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"LXRX":0.9},"content_text":"Lexicon Study Finds Sotagliflozin Improves Outcomes in HFpEF Patients Without Diabetes\n    \n\n        Lexicon Pharmaceuticals Inc. has announced new clinical data from a study evaluating sotagliflozin in patients with heart failure with preserved ejection fraction (HFpEF) without diabetes. The results were presented at the American Heart Association (AHA) Annual Scientific Sessions 2025. The randomized, double-blind, placebo-controlled trial, conducted under the direction of Dr. Juan J Badimon at Mount Sinai Medical Center, enrolled 88 racially diverse participants, 70 percent of whom were female. Over a six-month treatment period, patients receiving sotagliflozin demonstrated statistically significant improvements in left ventricular mass, diastolic function, six-minute walk test performance, and Kansas City Cardiomyopathy Questionnaire (KCCQ) scores compared to placebo. While peak VO2 improvement was not statistically significant, a notable trend was observed. This study is reported as the first to demonstrate clinical benefits of sotagliflozin for HFpEF patients without diabetes.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571873-en) on November 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582817000","isCrawlerRequest":true}